Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs

被引:117
作者
Mold, C
Gresham, HD
Du Clos, TW
机构
[1] Vet Affairs Med Ctr, Res Serv 151, Dept Mol Genet & Microbiol, Albuquerque, NM 87108 USA
[2] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA
关键词
D O I
10.4049/jimmunol.166.2.1200
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pentraxins, serum amyloid P component (SAP) and C-reactive protein (CRP) are acute-phase serum proteins in mice and humans, respectively. Although SAP binds to DNA and chromatin and affects clearance of these autoantigens, no specific receptor for SAP has been identified. CRP is an opsonin, and we have shown that it binds to Fc gammaR. Mice deficient in Fc gammaR were used to assess the role of these receptors in phagocytosis by pentraxins using zymosan as a ligand. Phagocytosis of zymosan by bone marrow macrophages (BMM) was enhanced by opsonization with SAP or CRP. BMM from mice deficient in all three Fc gammaR or in gamma -chain ingested unopsonized zymosan, but phagocytosis of SAP- or CRP-opsonized zymosan was not enhanced. SAP binding to BMM from gamma -chain-deficient mice was also greatly reduced, indicating little or no binding of SAP to Fc gamma RII, SAP and CRP opsonized zymosan for phagocytosis by BMM from mice deficient in Fc gamma RII or Fc gamma RIII, SAP, but nut CRP, opsonized zymosan for uptake by neutrophils that express only low levels of Fc gamma RI. Together these results indicate that Fc gamma RI and Fc gamma RIII are receptors for SAP in the mouse. Opsonization of zymosan by CRP is mediated through Fc gamma RI. Pentraxins are major proteins of the innate immune system and arose earlier in evolution than Igs. The use of Fc gammaR by the pentraxins links innate and adaptive immunity and may have important consequences for processing, presentation, and clearance of the self-Ags to which these proteins bind.
引用
收藏
页码:1200 / 1205
页数:6
相关论文
共 37 条
  • [1] The major receptor for C-reactive protein on leukocytes is Fcγ receptor II
    Bharadwaj, D
    Stein, MP
    Volzer, M
    Mold, C
    Du Clos, TW
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) : 585 - 590
  • [2] Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
    Bickerstaff, MCM
    Botto, M
    Hutchinson, WL
    Herbert, J
    Tennent, GA
    Bybee, A
    Mitchell, DA
    Cook, HT
    Butler, PJG
    Walport, MJ
    Pepys, MB
    [J]. NATURE MEDICINE, 1999, 5 (06) : 694 - 697
  • [3] Burlingame RW, 1996, J IMMUNOL, V156, P4783
  • [4] CLAUS DR, 1976, J LAB CLIN MED, V87, P120
  • [5] Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors
    Clynes, R
    Maizes, JS
    Guinamard, R
    Ono, M
    Takai, T
    Ravetch, JV
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) : 179 - 185
  • [6] FIBRONECTIN AND C4-BINDING PROTEIN ARE SELECTIVELY BOUND BY AGGREGATED AMYLOID-P COMPONENT
    DEBEER, FC
    BALTZ, ML
    HOLFORD, S
    FEINSTEIN, A
    PEPYS, MB
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 154 (04) : 1134 - 1149
  • [7] The interaction of C-reactive protein and serum amyloid P component with nuclear antigens
    DuClos, TW
    [J]. MOLECULAR BIOLOGY REPORTS, 1996, 23 (3-4) : 253 - 260
  • [8] DECREASED AUTOANTIBODY LEVELS AND ENHANCED SURVIVAL OF (NZB X NZW) F(1) MICE TREATED WITH C-REACTIVE PROTEIN
    DUCLOS, TW
    ZLOCK, LT
    HICKS, PS
    MOLD, C
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 70 (01): : 22 - 27
  • [9] DUCLOS TW, 1991, J BIOL CHEM, V266, P2167
  • [10] Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III
    Fossati-Jimack, L
    Ioan-Facsinay, A
    Reininger, L
    Chicheportiche, Y
    Watanabe, N
    Saito, T
    Hofhuis, FMA
    Gessner, JE
    Schiller, C
    Schmidt, RE
    Honjo, T
    Verbeek, JS
    Izui, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (08) : 1293 - 1302